… In this retrospective study, we aimed to explore the efficacy and safety profile of apatinib
monotherapy, or combined with chemotherapy or EGFR-TKI for treatment of brain metastases in …

… In summary, the aim of this trial is to demonstrate the clinical efficacy and safety of concurrent
BR and apatinib in patients with driver mutation-negative NSCLC with multiple BMs, in …

… evaluated the safety and efficacy of apatinib combined with concurrent brain radiotherapy
in … So far, there is no definite evidence that apatinib can enter the blood-brain-barrier, but a …

… We aimed to assess the efficacy and safety of apatinib in patients … apatinib in 2 patients with
brain metastasis and primary brain tumor, respectively, and the results showed that apatinib (…

… the safety and efficacy of concurrent brain … metastatic lesions, apatinib in our case as well
as bevacizumab received CR. The outcome may due to angiogenic agents, as well as the brain …

… radiotherapy, and radiotherapy is known to inhibit tumor and alter BBB permeability, [35]
further study is still required to illustrate the inhibitory effect of apatinib on brain metastasis. …

… We further assessed the efficacy and safety of apatinib at a more frequently used dose of
500 mg qd. The preliminary clinical outcome of apatinib in patients with brain metastases was …

… Based on this review, keeping systemic treatments concurrently with SRS appears to be safe
in the case of ICI, BRAFi, osimertinib, lapatinib, gefitinib, icotinib, trastuzumab, bevacizumab…

… safety of apatinib combined with WBRT in NSCLC patients with symptomatic multiple brain
metastases … a low-dose apatinib in combination with WBRT was effective and safe with no …

… and treated with apatinib 500 mg … apatinib might be effective in the treatment of recurrent
glioma [14]. Our prospective study aimed to further evaluate the efficacy and safety of apatinib …